TScan Therapeutics Provides Update On Its Solid Tumor And Heme Malignancies Clinical Programs
TScan Therapeutics Provides Update On Its Solid Tumor And Heme Malignancies Clinical Programs
tScan Therapeutics 提供其實體瘤和血紅素惡性腫瘤臨床項目的最新情況
Over 40 solid tumor patients have completed all biomarker testing in the screening protocol; ~60% of these patients qualify for at least one TCR-T in the ImmunoBank and ~30% are eligible for multiplex therapy. Patients identified across all six TCR-T cohorts in solid tumor program with dosing of first three expected in early May. All eight patients in the heme program treated with TSC-100 or TSC-101 remain relapse-free with no detectable cancer to date; median follow-up of >10 months.
超過40名實體瘤患者已完成篩查方案中的所有生物標誌物測試；其中約60％的患者有資格在ImmunoBank中接受至少一項TCR-T，約30％有資格接受多重治療。在實體瘤項目的所有六個TCR-T隊列中都確定了患者，預計前三組患者將在5月初給藥。血紅素項目中接受 TSC-100 或 TSC-101 治療的所有八名患者都沒有復發，迄今爲止沒有可檢測到的癌症；隨訪中位數大於 10 個月。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。